CN101925600B - (r)-3-氟苯基-3,4,5-三氟苯甲基氨基甲酸1-氮杂二环[2,2,2]辛-3-基酯的稳定结晶盐 - Google Patents

(r)-3-氟苯基-3,4,5-三氟苯甲基氨基甲酸1-氮杂二环[2,2,2]辛-3-基酯的稳定结晶盐 Download PDF

Info

Publication number
CN101925600B
CN101925600B CN2008801254506A CN200880125450A CN101925600B CN 101925600 B CN101925600 B CN 101925600B CN 2008801254506 A CN2008801254506 A CN 2008801254506A CN 200880125450 A CN200880125450 A CN 200880125450A CN 101925600 B CN101925600 B CN 101925600B
Authority
CN
China
Prior art keywords
compound
acid
tartrate
salt
crystallization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801254506A
Other languages
English (en)
Chinese (zh)
Other versions
CN101925600A (zh
Inventor
J·L·卡特纳鲁茨
J·希达尔戈罗德里古茨
M·D·C·塞拉科马斯
I·马西普马西普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Salvat SA
Original Assignee
Laboratorios Salvat SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Salvat SA filed Critical Laboratorios Salvat SA
Publication of CN101925600A publication Critical patent/CN101925600A/zh
Application granted granted Critical
Publication of CN101925600B publication Critical patent/CN101925600B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2008801254506A 2007-11-28 2008-11-26 (r)-3-氟苯基-3,4,5-三氟苯甲基氨基甲酸1-氮杂二环[2,2,2]辛-3-基酯的稳定结晶盐 Expired - Fee Related CN101925600B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07384038.1 2007-11-28
EP07384038A EP2065385A1 (en) 2007-11-28 2007-11-28 Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
PCT/EP2008/010012 WO2009068253A2 (en) 2007-11-28 2008-11-26 Stable crystalline salt of (r)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.2]oct-yl ester

Publications (2)

Publication Number Publication Date
CN101925600A CN101925600A (zh) 2010-12-22
CN101925600B true CN101925600B (zh) 2013-01-09

Family

ID=39401152

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801254506A Expired - Fee Related CN101925600B (zh) 2007-11-28 2008-11-26 (r)-3-氟苯基-3,4,5-三氟苯甲基氨基甲酸1-氮杂二环[2,2,2]辛-3-基酯的稳定结晶盐

Country Status (18)

Country Link
US (2) US8492402B2 (enExample)
EP (2) EP2065385A1 (enExample)
JP (1) JP5336509B2 (enExample)
KR (1) KR101557832B1 (enExample)
CN (1) CN101925600B (enExample)
AU (1) AU2008329181B2 (enExample)
BR (1) BRPI0819607A2 (enExample)
CA (1) CA2706565C (enExample)
DK (1) DK2220082T3 (enExample)
EA (1) EA017483B1 (enExample)
ES (1) ES2498819T3 (enExample)
IL (1) IL206032A (enExample)
MX (1) MX2010005850A (enExample)
NZ (1) NZ585833A (enExample)
PL (1) PL2220082T3 (enExample)
UA (1) UA102083C2 (enExample)
WO (1) WO2009068253A2 (enExample)
ZA (1) ZA201003718B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002228015B2 (en) 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
JP5745283B2 (ja) † 2010-02-12 2015-07-08 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体
KR101978364B1 (ko) 2017-06-15 2019-05-14 크리스탈지노믹스(주) 알킬카바모일 나프탈렌일옥시 옥테노일 하이드록시아마이드 또는 그 유도체의 약학적으로 허용 가능한 염 및 그 제조방법
KR102678356B1 (ko) * 2018-10-29 2024-06-26 씨지인바이츠 주식회사 알킬카바모일 나프탈렌일옥시 옥테노일 하이드록시아마이드 인산염, 타르타르산염 또는 이들의 조합을 포함하는 약제학적 조성물 및 그 제조방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1300407A1 (en) * 2000-06-27 2003-04-09 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE510305C2 (sv) * 1997-05-30 1999-05-10 Astra Ab Nytt salt
AU2002228015B2 (en) * 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
EA006505B1 (ru) * 2001-12-20 2005-12-29 Лабораториос С.А.Л.В.А.Т.,С.А. Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1300407A1 (en) * 2000-06-27 2003-04-09 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Huang LianFeng et al..Impact of solid state properties on developability assessment of drug candidates.《Advanced Drug Delivery Reviews》.2004,第56卷(第3期),321-334. *

Also Published As

Publication number Publication date
EP2220082B1 (en) 2014-06-25
MX2010005850A (es) 2010-09-03
ES2498819T3 (es) 2014-09-25
KR101557832B1 (ko) 2015-10-06
DK2220082T3 (da) 2014-10-06
NZ585833A (en) 2011-05-27
JP2011504890A (ja) 2011-02-17
EP2220082A2 (en) 2010-08-25
HK1144192A1 (en) 2011-02-02
EA201070651A1 (ru) 2010-12-30
AU2008329181A1 (en) 2009-06-04
US20110207769A1 (en) 2011-08-25
WO2009068253A2 (en) 2009-06-04
US8871787B2 (en) 2014-10-28
CA2706565C (en) 2015-04-28
PL2220082T3 (pl) 2014-12-31
CN101925600A (zh) 2010-12-22
CA2706565A1 (en) 2009-06-04
KR20100103532A (ko) 2010-09-27
AU2008329181B2 (en) 2012-03-29
BRPI0819607A2 (pt) 2015-10-13
WO2009068253A3 (en) 2009-08-13
JP5336509B2 (ja) 2013-11-06
UA102083C2 (uk) 2013-06-10
EP2065385A1 (en) 2009-06-03
IL206032A (en) 2014-07-31
US20140051721A1 (en) 2014-02-20
ZA201003718B (en) 2011-08-31
IL206032A0 (en) 2010-11-30
EA017483B1 (ru) 2012-12-28
US8492402B2 (en) 2013-07-23

Similar Documents

Publication Publication Date Title
CN102448963B (zh) 7-[(3R,4R)-3-羟基-4-羟基甲基-吡咯烷-1-基甲基]-3,5-二氢-吡咯并[3,2-d]嘧啶-4-酮的有用药学上的盐
KR102618114B1 (ko) 이브루티닙과 카복실산의 공결정체
DE60114617T2 (de) Zolpidem hemitartrat
CN107400134A (zh) 嘌呤衍生物的结晶形式
WO2008021342A2 (en) Amorphous and crystalline forms of 9-hydroxy-risperidone ( paliperidone )
JP2016509031A (ja) トレラグリプチンの固形形式及びその製造方法と用途
CN101925600B (zh) (r)-3-氟苯基-3,4,5-三氟苯甲基氨基甲酸1-氮杂二环[2,2,2]辛-3-基酯的稳定结晶盐
US20120122915A1 (en) Crystalline forms of palonosetron hydrochloride
EP2524921A1 (en) Novel Crystalline Salts of Asenapine
WO2006104997A2 (en) Tartaric acid salts of a dipeptidyl peptidase-iv inhibitor
US9670156B2 (en) Crystal form III of (S)-oxiracetam, preparation method and use thereof
WO2000073303A1 (en) Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists
US20020193386A1 (en) Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
CN113929629B (zh) 一种吉非替尼的酸加成盐
HK1144192B (en) Stable crystalline salt of (r)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
EP3181565A1 (en) Crystalline omarigliptin salts
CN116217574A (zh) 一种利格列汀-烟酸共晶体
CN104725377A (zh) 一种盐酸莫西沙星的新晶型及其制备方法
JP5589097B2 (ja) ダサチニブ多結晶体、並びにその調製方法及び薬物組成物
TW202448848A (zh) Ｅｐ４拮抗劑的晶型
KR20170078036A (ko) 무정형 리나글립틴의 제조 방법
CN114671826A (zh) 一种莫沙必利有机酸晶体
EP2133352A2 (en) Crystal form of 9-hydroxy-risperidone (paliperidone)
EP2133351A2 (en) Crystal form of 9-hydroxy-risperidone (paliperidone)
US20030191140A1 (en) Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130109

Termination date: 20161126

CF01 Termination of patent right due to non-payment of annual fee